Logo 1 Logo 2

Investigational Drug Details

Drug ID: D353
Drug Name: Zopiclone
Synonyms:
Type: small molecule
DrugBank ID: DB01198
DrugBank Description: Zopiclone is a novel hypnotic agent used in the treatment of insomnia. Its mechanism of action is based on modulating benzodiazepine receptors. In addition to zopiclone's benzodiazepine pharmacological properties it also has some barbiturate like properties.
PubChem ID: 5735
CasNo: 43200-80-2
Repositioning for NAFLD: Yes
SMILES: CN1CCN(CC1)C(=O)OC1N(C(=O)C2=NC=CN=C12)C1=NC=C(Cl)C=C1
Structure:
InChiKey: GBBSUAFBMRNDJC-UHFFFAOYSA-N
Molecular Weight: 388.808
DrugBank Targets: Gamma-aminobutyric acid receptor subunit alpha-1; Gamma-aminobutyric acid receptor subunit alpha-2; Gamma-aminobutyric acid receptor subunit alpha-3; Gamma-aminobutyric acid receptor subunit alpha-5; Translocator protein
DrugBank MoA: Zopiclone exerts its action by binding on the benzodiazepine receptor complex and modulation of the GABA<sub>B</sub>Z receptor chloride channel macromolecular complex. Both zopiclone and benzodiazepines act indiscriminately at the benzodiazepine binding site on α1, α2, α3 and α5 GABAA containing receptors as full agonists causing an enhancement of the inhibitory actions of GABA to produce the therapeutic (hypnotic and anxiolytic) and adverse effects of zopiclone.
DrugBank Pharmacology: Zopiclone is a nonbenzodiazepine hypnotic from the pyrazolopyrimidine class and is indicated for the short-term treatment of insomnia. While Zopiclone is a hypnotic agent with a chemical structure unrelated to benzodiazepines, barbiturates, or other drugs with known hypnotic properties, it interacts with the gamma-aminobutyric acid-benzodiazepine (GABA<sub>B</sub>Z) receptor complex. Subunit modulation of the GABA<sub>B</sub>Z receptor chloride channel macromolecular complex is hypothesized to be responsible for some of the pharmacological properties of benzodiazepines, which include sedative, anxiolytic, muscle relaxant, and anticonvulsive effects in animal models. Zopiclone binds selectively to the brain alpha subunit of the GABA A omega-1 receptor.
DrugBank Indication: For the short-term treatment of insomnia.
Targets:
Therapeutic Category:
Clinical Trial Progress:
Latest Progress: